

Available online on 15.04.2019 at <http://jddtonline.info>

# Journal of Drug Delivery and Therapeutics

Open Access to Pharmaceutical and Medical Research

© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted non-commercial use, provided the original work is properly cited

Open  Access

Research Article

## Formulation and Development OF BCS Class II Drug

Marapur S C<sup>\*1</sup>, Dr Rakesh Kumar Jat<sup>2</sup>, Dr J S Patil<sup>3</sup><sup>1</sup> B.L.D.E.A's SSM College of pharmacy vijayapura B.L.D.E University campus-586101, India<sup>2</sup> Dept. of Pharmaceutical Science JJT University Rajasthan, India<sup>3</sup> VT' Shivajirao S. Jondhle College of Pharmacy, Thane, Maharashtra, India

### ABSTRACT

The aim of this research was to develop and evaluate liquisolid compacts of Voriconazole a BCS class II drug. The series of formulations containing Voriconazole drug were formulated by using aerosil a colloidal silicone dioxide and avicel PH microcrystalline cellulose in different ratios by using suitable solvent. Solubility studies were performed in propylene glycol and polyethylene glycol (PEG-200, 400, 600) for the choice of the best nonvolatile liquid to dissolve Voriconazole. On the basis of the solubility data PEG 600 was chosen as a good solvent for the Voriconazole. Voriconazole was dissolved in solvent PEG 600 for the preparation of solution of drug. Formulated compacts were evaluated for all post compression parameters and the in-vitro drug release study was carried out. All the formulations have shown a very good drug release in 15 min except compressibility problems due to higher loading factor of liquid vehicle for the formulations. The selected formulation FV10 containing 30% of drug solution has shown good drug release of 100.2% in 15 min compared to dissolution of pure drug and marketed tablet which shown 58.55% and 70.6 % respectively. No interactions were found between drug and polymers in FITR as well as DSC. XRD of selected formulation shows that drug present in the formulation is in amorphous form.

**Keywords:** Voriconazole HCl, Avicel PH, Aerosil 200, Poly-Ethylene Glycol 600, liquisolid compacts.

**Article Info:** Received 26 Feb 2019; Review Completed 07 April 2019; Accepted 11 April 2019; Available online 15 April 2019



### Cite this article as:

Marapur SC, Jat RK, Patil JS, Formulation and Development OF BCS Class II Drug, Journal of Drug Delivery and Therapeutics. 2019; 9(2-s):486-493 <http://dx.doi.org/10.22270/jddt.v9i2-s.2579>

### \*Address for Correspondence:

Marapur S C, B.L.D.E.A's SSM College of pharmacy vijayapura B.L.D.E University campus-586101, India

### INTRODUCTION

The oral administration is the route of choice and is the very much preferred route for administration of drug due to more patient fulfillment (or) acceptance in the drug development. Because of some associated problems caused by this route of administration, this is complicated to achieve the plasma drugs concentrations. The drug solubility is a biggest problem and it is the most important to attain the required amount of drug into the blood.<sup>1</sup>

The drugs have incomplete bioavailability which is less water soluble and having less dissolution rate. The challenge of slightly solubility of drug in water is to develop the solubilization and dissolution of drug. Various types of techniques that can be utilized to develop the solubilization of less water soluble and water insoluble active constituent, like reduction of particle size into microns, freeze drying, dispersion of drug into solubilising agent, using complex forming agents, co solvents, chemically modifications, adjusting pH, solubilization with surface active agents, Solid solution, encapsulation of drug in liquid form into the soft gelatin capsule, formation of salt. The techniques like these

were introduced to develop the drug solubility and to boost the absorption of drug and drug bioavailability. The liquisolid compact is admissible fluidly and is a compressible powder form of liquid medicament. A liquid portion, which may be an oily liquid medicament, suspensions or solutions of poorly water soluble drug in an appropriate solvent vehicle of nonvolatile, is included in the carrier agent of porous nature. During the saturation point of carrier with solvent, formation of solvent layer takes place over the surface of particles which then get adsorbed fatty by the coating particles of fine nature. In this way, a clearly dry easy flowing powder for compressibility is obtained. The concentrations of carrier, coating material, disintegrant, lubricant and glidant are optimized to obtain a non-stick readily compressible mixture. These techniques were introduced to progress the drug solubility molecule also to enhancement of absorption and also drug bioavailability. The method of solid dispersion is significant for the enhancement of drug solubilization, its wetting property, and to boost the drug solubility and bioavailability. In order to solve all such type of problems, the "Liquisolid Technique

"was developed which may called as the Technology of Powder solution

Hence main objectives of this present study were to carry out the solubility enhancement technique for the BCS class II drugs by using the liquisolid compact technique.<sup>2</sup>

## MATERIALS AND METHODS

Materials: VoriconazoleHcl is received as gift sample from Gland pharmaHyderabad colloidal silicone dioxide (Aerosil 200), Microcrystalline cellulose (Avicel PH 101) are

received from Microlabs Bangalore and solvents like Propylene Glycol, PEG solvents are used of laboratory grades purchased from SD fine chemicals Mumbai. All other solvents and reagents were used as analytical grade.

### Determination of solubility of Voriconazole drug:

Solubility studies were performed in propylene glycol and polyethylene glycol (PEG-200, 400, 600) for the choice of the best non volatile liquid to dissolve Ezetimibe. Saturated solutions have been developed by the addition of surplus medications to solvent vehicles and stirring in a shaker incubator for 48 hours at  $25 \pm 1^\circ \text{C}$ . Following this stage the filtration was done by a filter of  $0.45 \mu\text{m}$  Millipore, by diluting using distilled water and done analysis by a the help of UV visual spectral in the wavelength of 255 nm against the blank in a solvent of non volatile in nature is the most significant quality of liquisolid system. The drug solubilization helps in the molecular dispersion in non volatile solvents like that may get improvement in the rate of dilution. On the basis of the solubility data PEG 600 was chosen as a good solvent for the Ezetimibe.

### Preparation of liquisolid compacts:

Voriconazole was dissolved without changing solvent PEG 600 for the preparation of solution of drug. The combination of coating and carrier materials transferred Avicel PH102 as carrier and colloidal silicon dioxide (Aerosil 200) as the coating adjuvant which was then added to the solvent and mixed in ceramic mortar to avoid over-trituration and reduce particle size. The blend was done in three phases; in the first phase, the drugs are slowly mixed to get even distribution of solvent medications. In the next stage, the blend was spreaded as a homogeneous coat on the surface and remained in position for a some minutes of interval. In last phase addition of 5% of disintegrating agent (Croscarmellose) was done to the granules or powder and mixed completely. The last blend is compressed into compacts by using 12 mm punches of round flat type in 16 station rotary tablet machine.<sup>3</sup>

### Evaluation of liquisolid compacts

#### Determining the drug solubility

Solubility studies had been conducted to choose the higher solubilization of the pure drug model in solvents like nonvolatile nature, which includes drugs solubilized in various solvents of nonvolatile. The quantities of excess net drugs were added to non-volatile solvents, followed by a transfer of saturation solution to rotary transformers for 48 hours at  $25^\circ\text{C}$  under continuous vibration. After a period of 48 hours the saturated solution is filtered by using a filter like Millipore of  $0.45 \mu\text{m}$  and analyzed.

Solubility studies were performed in the solvents propylene glycol and polyethylene glycol (PEG-200, 400, 600) to select the best non-volatile solvent to dissolve Voriconazole. Saturated solutions have been developed by the addition of excess medications to vehicles and stirring in a shaker

incubator for 48 hours at  $25 \pm 1^\circ \text{C}$ . After this period the solutions were filtered through a filter of  $0.45 \mu\text{m}$  Millipore, diluted with distilled water and distributed by a double radius of visible UV spectral spectrum in the wavelength of 255 nm.

### Determination of angle of slide

Many standard liquid compounds/powder mixtures containing 10 grams of carrier or coating material are prepared with increasing amounts of liquid vehicles. To measure the angle of slide, the liquid mixtures/powder of Voriconazole was placed on polished metal plates, and then gradually imbalanced until the liquid/powder was slid on the verge of slipping. The angle that is formed between the panel and the horizontal surface is defined as the angle of the slide.

### Calculation of the loading factor:

In the liquisolid system, the microcrystalline cellulose and aerosol could only keep definite amount of solvent by the maintenance of the satisfactory flow also compressibility characteristics according to the ratio used. The ratio of powder found in was R where  $R = Q/q$  of powder or granules are stated like fraction of carrier adjuvant (q) and the coating adjuvant materials (q) of the system. It is possible to set up the Voriconazole liquisolid system, which is transferable with an acceptable flow and the possibility of compression if it does not exceed the maximum fluid limit in the carrier's material. This nature of liquid is called a liquid or solvent loading factor (LF) and may be stated as the weight fraction of solvent medicine (W) and the adjuvant carrier (q) in the method where  $LF = w/q$ . For computation of the liquid or solvent load factor, solvents (liquid drugs without medication) with nonvolatile have been included to 10gm of carrier materials and collected for 1 minute then in this material addition of coating material done and mixed.

The formulations are designed for Voriconazole liquisolid systems according to the mathematical model described by Spireas et al. According to the theories of liquisolid tablets, the powder carrier and coating agents can only hold definite amounts of solvents and maintains an acceptable flow and compressible force. The fraction of powder in ratio R is known as

$$R = Q/q \text{ ——— (1)}$$

Where R is the fraction of carrier weight (Q) and (q) of the coating material found in the formulations. The liquid load factor (LF) is defined as the weight fraction of the liquid drug (W) to the weight of the carrier (Q) in the system, which must be present in the flowing system and the compressibility.

$$LF = W/Q \text{ ——— (2)}$$

$$LF = W/Q \text{ ——— (2)}$$

The ability to flow liquid retention ( $\theta$  value) of powder absorbent material was used to calculate the required quantities of components. Therefore, the powder rates R and the liquid load factor LF of the formulations are related to the following way

$$\text{Loading factor} = \Phi C A + \Phi C O * 1 / R.$$

$$W = \text{wt. of liquid drug, } Q = \text{wt. of carrier material}$$

$$Q = W/LF \text{ (4) } q = Q/R \text{ (5)}$$

Where, Q is carrier agent and q is the coating agent.<sup>4</sup>

### Evaluation of Voriconazole Liquefied tablets (post compression parameter)

The compression parameters of the Voriconazole Liquefied tablets are as follows.

#### Tablets Size and shape:

The size of tablets and tablets shapes can be explained as dimensions watched and controlled. It is found by the machine throughout the process of compression.

#### Determination of Moisture of Granules:

The granules or powders must have enough strength to resist normal process during handle of mixture and incorporation processes without production of big amount of fine dust. In some size decreasing process throughout the process of condense in the tablets is useful to represent the areas of the fresh surfaces required for best possible link to put so the dampness content is the very vital thing for fine medicinal products.

#### Weight Variation Test:

As per the USP the test for tablets weight variations test of the tablets Voriconazole Liquefied is made by weighing 20 compacts independently by calculated common weights and compared the weight of individual tablet on mean weight. The variation in weights of tablets in test is denominated by percentage. The formula used for same weight variation test =  $(iw-aw)/aw \times 100\%$  where, iw = Individual or single weight of tablet. aw = average or mean weight of tablet. According to USP the tablet comply with the tests if no extra than 2 out of single weights diverge as of the mean mass by additional than the proportion divergence as shown in table.<sup>5</sup>

#### Drug content uniformity:

**Standard preparation:** About 20 mg of Voriconazole was weighed accurately and shift to a flask of 50 ml. and dissolve then dilute and fill up to the volume with the Phosphate solution 7.4 pH and mixed.

**Preparation of sample solution:** Five tablets were taken powdered and weighed into powder. The powder equal to 20 mg is taken by weighing accurately. Drug Voriconazole powder was transferred to a flask of 50 ml and made to dissolve in a 7.4 pH phosphate buffer. Sonication is done by keeping for 30 minutes and filtered using membrane filter 0.45. It is then dissolved and diluted to the mark. The absorption of both after the appropriate dilutions was measured in a UV-visible spectrophotometer at 255 nm of standard preparation and the preparation of the sample at 7.4 pH phosphate solutions. The repetition of method was done for 3 times.

**Thickness:** The tablet thickness of individual tablets was found with a sliding caliper scale of 5 or 10 tablets, where their total thickness was measured. The thickness of the tablet must be checked within a variation of  $\pm 5\%$  of a standard expressed in mm.

#### Hardness Test:

For this test tablet hardness tester, Monsanto hardness equipment is used to evaluate the hardness of tablet was used. The equipment contains a drum and a compressor spring which is held in between two divers. The piston is located to make contact with the tablet and receives reading at zero level. The piston which is upper side is moved with force in opposition to a spring by rotating a thread lock till the tablet breaks. When the compression of spring is done,

an indicator reads alongside a meter in the drum to point out strength. The force of the break is noted in a k.g. Ten Voriconazole liquefied compacts are compressed and measured their hardness and the permissible range in between 4-6 kg (40-60 N) if not or else noted.

**Friability test:** The test for Friability of tablets can find experimentally by Roche Friabilator. To test weight of twenty Voriconazole liquefied compacts are taken and kept in the Friabilator and then rotated at 25 Rotations per minute until 240 seconds. The tablet weight is noted again by dusting. The variation of two weights in tablets is noted to compute the friability and the reading and is noted. This was found by using the formula:

$$\text{Friability} = \frac{(IW-FW)}{IW} \times 100\%$$

Where, IW = initial weight of compacts FW = final weight of compacts. As per USP the compacts that loss is lesser than 0.5% to 1% (after 100 rotations) of their weights are usually considered as satisfactory.

#### Disintegration test:

USP devices containing 6 glass or plastic tubes which are 3 inches in length, open at the top, and covered by 10 no. net screen towards the base end of the basket stand apparatus. For checking the disintegrate time, a Voriconazole liquefied compact is kept on every tube and the set of basket is placed in a specific media at  $37 \pm 2^\circ \text{C}$ , as the compacts leftovers 2.5 cm under the liquid surface in the movement towards ascending and descending is no nearer than 2.5 centimeters from the base of the container. A model machine device is utilized to move the basket assemble which contains the tablets top and bottom throughout the space of 5 to 6 cm. At a occurrence of 28 to 32 revolutions per minute. Plastic discs of perforated may be used in the study. The compacts are kept at the top of s and transmit a rough stroke on the tablets. Discs may be or may not be necessary or provide additional sensitivity to the study, but these are helpful for floating of compacts or tablets. Function the device for the specific time (900seconds for compacts of un coated, if not or else acceptable and permitted)

The compacts comply as per the test if the compacts are dissolved, and all drug particles pass through the mesh at the specified time. If filtrate remains, it should have a soft mass without a clearly stable nucleus. The compacts comply with the study as per the USP, if all the compacts have been fully dissolved. If the 1 or 2 compacts fail to dissolve totally, repetition of the test should be done for 12 supplementary compacts. If the condition is not met then not lesser than 16 of the 18 compacts are to be tested.<sup>6</sup>

**In vitro dissolution study of Voriconazole liquefied compacts:** release of medications from liquefied tablets has been determined using the USP type II (paddle). Followed the test through three steps if not the outcome match both S1 and S2. The Q amount is the particular quantity of active constituent dissolved, noted in a percentage of the nominal. 5% 15% and 25 % values and are named content modifiers, so that these values and Q are under the same conditions.

Standard solution: 0.1 N HCl

Size 500 ml;

Temperature maintained  $37^\circ \text{C} \pm 0.5^\circ \text{C}$

Speed of paddle: 50 rpm.

Process: 5 ml of the media were withdrawn every time at the appropriate intervals of 10, 20, 30 and L. 45 and replaced by a fresh solution. After withdrawal of the sample filtration was made and analyzed after dilution using a double beam of UV spectrophotometer at 255nm.<sup>7</sup>

## RESULT AND DISCUSSION

### Standard calibration curves of Voriconazole drug in 0.1 N HCl:

The calibrations curve of Voriconazole drug was plotted by the absorbance v/s concentrations. The  $\lambda_{\max}$  of Voriconazole drug in **in 0.1 N HCl** was determined at  $\lambda_{\max}$  255 nm. The values of absorbance are shown in table. The standard calibrations curve of Voriconazole is in the Beer's range between 10-60  $\mu\text{g/ml}$ .

### Determination of solubility of Voriconazole drug:

Solubility studies were performed in propylene glycol and polyethylene glycol (PEG-200, 400, 600) for the choice of the best non volatile liquid to dissolve Ezetimibe. Saturated solutions have been developed by the addition of surplus medications to solvent vehicles and stirring in a shaker incubator for 48 hours at  $25 \pm 1^\circ \text{C}$ . Following this stage the filtration was done by a filter of 0.45  $\mu\text{m}$  Millipore, by diluting using distilled water and done analysis by the help of UV visual spectral in the wavelength of 255 nm against the blank in a solvent of non volatile in nature is the most significant quality of liquisolid system. The drug solubilization helps in the molecular dispersion in non volatile solvents like that may get improvement in the rate of dilution. On the basis of the solubility data PEG 600 was chosen as a good solvent for the Ezetimibe.

### Determination of Angle of slide:

Many standard solvent compounds or powder mixtures which contain 10 grams of carrier or coating material are prepared with increasing amounts of liquid vehicles. To determine the angle of slide, the solvent or powder prepared from Voriconazole kept on metal plate which is polished, and then slanted steadily until the liquid or powder mixture was get slided. The angle that is formed between the panel and the surface which is horizontal is stated as the angle of slide (h).

### The Angle of repose:

The angle of repose of these powders is formed due to the effect of the inner particles of strong friction. The most cohesive molecules in nature have a higher angle of repose. Angle of repose smaller than thirty degrees shows good flow nature from a 40 degree angle and above shows poor flow. Formulations with an angle of repose superior than 40 are not satisfactory (F1-F12 and F13-f16 formulations) combinations, F10 and F11 shown 27 degrees, and 28 degrees respectively, showed a good flow, but the F10 formula necessary in a larger quantity of carrier adjuvant that improved the size of the compact to 455 mg. So the F10 preparation was chosen for compression.

### Bulk density and tapped density:

The acceptable range and values summarized in table indicate the values for all combinations from F1 to F16 in Voriconazole formulations. This outcome helps to calculate the percentage of the powder compressibility within the acceptable limit.

**Carr's Index:** Based on these parameters, the F11 formulation was chosen for further evaluation. Formulation

F10 showed Carr index 22.47 and Hausner ratio of 1.15 to the total weight of the tablet of 455 mg.

### Post compression Parameters of Voriconazole Liquisolid compacts:

**Hardness:** The liquisolid system must have sufficient hardness to prevent breakage during manipulation, and also must be disintegrate. The formulation of F10 also showed a very good hardness of about  $4.5 \text{ kg/cm}^2$ .

**Thickness:** The thickness values of F1 to F16 formulas are almost uniform in all formulas.

**Friability test:** The friability results of the Voriconazole liquisolid compacts have been found within the approved range ( $< 1\%$ ) and formulations from F1 to F16 and possess good mechanical strength.

**Weight variation test:** The percentage of tablets weight variations were found for the formulations F1 to F16. The values observed were within the acceptable limit.

**Drug content uniformity:** The liquisolid tablets were evaluated to standardize the drug content by selecting ten compacts randomly. The compacts were powdered then weighed 100 mg of the powder then shifted in a volumetric flask of 100 ml, and the content of drug was estimated by spectrophotometrically at 255 nm (Indian Pharmacopeia) The drug content for compacts of all the formulations ranges in between 96.6-99.9%. The results indicates that the tablets active contents of all the preparations were found to be identical and contains right dose of the active ingredients.

**Disintegration time:** The disintegration time of the tablets is given in Table 65 and was found to be 115 and 125 seconds for the FV10 and FV11 formulation. For formulations FV1 to FV9 and formulations FV12 to FV16 was observed to be 215 to 250 seconds.

**Dissolution study:** Dissolution studies of all formulations from FV1 to FV16 were carried out in 0.1N HCl. There is no great difference in the patent of all formulations due to the good solubility of the drug in the liquid or solvent except for the compressibility problems due to the higher loading factor of the liquid vehicle for preparations. All formulations showed very good drug release in 15 minutes. The selected formulation of FV10 containing 30% of a drug solution has shown good drug release of 100.20% over 15 minutes as compared to the dissolution of the pure drug and the tablet marketed which showed 58.5% and 70.60% respectively. The drug release data obtained for the FV10 formulation together with the pure drugs and tablets marketed.

### Drug-Excipient Interactions:

**DSC thermogram:** DSC of pure Voriconazole was showed a sharp peak of endotherm at  $188.67^\circ\text{C}$  with respect to its melting point, indicates the crystal character of the drug. DSC thermo grams of liquisolid compacts indicated broad peaks at  $128.56^\circ\text{C}$ , indicating a decreasing in the crystal nature of drug and its transform to amorphous form. A slight shift in the drug melting peaks indicating dissolution of drug in the non volatile liquid PEG 600 before reaching its fusion temperature. It was concluded that the presence of the drug affects the lattice energy of the crystalline polymer leading to shifting of the peak. The vanishing of drug peak in formulations into a liquisolid compacts indicate the absolute inhibition of all drug thermal characters certainly indicates the formation of an solid solution of amorphous. No other interactions were observed in between the drug and excipients.

**FT-IR spectra of VoriconazoleLSC:**

FTIR spectroscopy was utilized for the analysis of the changes in structure and interaction possibilities of between the drug and Liquisolid compacts of Ezetimibe. The characteristic peaks of Voriconazole was found to be 3200, 2400, 1200,800  $\text{cm}^{-1}$ . The FTIR spectrum of Liquisolid compacts of Voriconazole showed its characteristic IR absorption peaks at 3300, 2400, 1100, 650  $\text{cm}^{-1}$ . These spectra observations revealed no any interactions among the carrier and drug used.

**X-Ray Diffractometry (XRD) of VoriconazoleLSC:** The X-ray diffractogram of the Voriconazole Drug, Formulation F11 and Physical mixture. Voriconazole shows sharp peaks at  $16^\circ$ ,  $17.5^\circ$  and  $19^\circ$  and  $19.5^\circ$ . The nonexistence of distinguishing peak of Voriconazole in liquisolid compacts shows that drug is completely transformed into amorphous or solubilized appearance. The nonexistence of crystal nature of the drug in the liquisolid compacts may be due to the effect of solubilisation in the solvent material which was absorbed in the carrier material and adsorbed on the coating materials. The liquisolid system and physical mixture preparations have the same diffracting pattern and found no other peaks. The amorphization or solubilisation of Voriconazole has increased the dissolution rate.

**Stability Study:** The stability study was conducted for F10 formulations stored in  $40^\circ\text{C}/75\% \text{RH}$  for 30 days. The various parameters were studied such as hardness, friability,

drug contents uniformity, in vitro dissolution. There was not much variations observed in any parameters throughout study period of time. <sup>9,10</sup>

**CONCLUSION**

In this research, attempt was made to formulate liquisolid compacts by the use of Avicel PH and Aerosil 200, as carrier and coating material. Suitable solvent propylene glycol was selected based on solubility parameter and used as best solvent to dissolve Voriconazole. Liquid loading factor was calculated based on the solubility property of drug into the solvent. The prepared liquisolid powders are subjected to precompression parameters and compressed into the compacts. The post compression parameters of compacts were evaluated. In vitro dissolution of compacts shown a very good drug release except compressibility problems in formulations with high liquid load factor other than Formulations F10 and F11 having low liquid load factor. It was found that formulations F10 and F11 have shown a very good release and formulations F10 when compared to the pure drug and marketed product has shown a good release and was selected as a final formulation based on the total weight of the tablets and subjected to the final characterization along with stability study. Thus this technology has shown a potential drug release for poor water soluble drugs and proves to be a potential approach for the enhancement of solubility of poor water soluble drugs thus enhancing the bioavailability.

**Table 1: formulation of liquisolid compacts of voriconazole**

| Liquisolid system* | Drug concentration in PG (% w/w) | RR=Q/q | Lf Lf=W/Q | Avicel PH 102 Q = W/Lf | Aerosil 200 q=Q/R | Formulation wt (mg) |
|--------------------|----------------------------------|--------|-----------|------------------------|-------------------|---------------------|
| FV1                |                                  | 5      | 0.835     | 400                    | 80                | 575                 |
| FV2                | 15% (335ml)                      | 10     | 0.675     | 500                    | 50                | 650                 |
| FV3                |                                  | 15     | 0.55      | 600                    | 40                | 750                 |
| FV4                |                                  | 20     | 0.475     | 700                    | 35                | 850                 |
| FV5                |                                  | 5      | 0.83      | 300                    | 60                | 440                 |
| FV6                | 20%(250ml)                       | 10     | 0.625     | 400                    | 40                | 530                 |
| FV7                |                                  | 15     | 0.5       | 500                    | 33.3              | 630                 |
| FV8                |                                  | 20     | 0.415     | 600                    | 30                | 740                 |
| FV9                |                                  | 5      | 0.67      | 150                    | 30                | 245                 |
| FV10               | 40%(125ml)                       | 10     | 0.4       | 250                    | 25                | 345                 |
| FV11               |                                  | 15     | 0.28      | 350                    | 23.33             | 455                 |
| FV12               |                                  | 20     | 0.22      | 450                    | 22.5              | 565                 |
| FV13               |                                  | 5      | 0.67      | 100                    | 20                | 175                 |
| FV14               | 60%(85ml)                        | 10     | 0.33      | 200                    | 20                | 285                 |
| FV15               |                                  | 15     | 0.22      | 300                    | 20                | 400                 |
| FV16               |                                  | 20     | 0.165     | 400                    | 20                | 505                 |

Table 2. Precompression parameters of liquisolid powders :

| F No | Angle of | Bulk | Tapped | Carr's | Hausner's |
|------|----------|------|--------|--------|-----------|
| FV1  | 42       | 0.79 | 0.95   | 20.22  | 1.20      |
| FV2  | 41       | 0.78 | 0.95   | 22.22  | 1.21      |
| FV3  | 41       | 0.75 | 0.91   | 20.07  | 1.21      |
| FV4  | 40       | 0.72 | 0.91   | 21.00  | 1.26      |
| FV5  | 41       | 0.70 | 0.88   | 21.50  | 1.25      |
| FV6  | 40       | 0.73 | 0.91   | 20.87  | 1.24      |
| FV7  | 40       | 0.70 | 0.90   | 22.22  | 1.26      |
| FV8  | 39       | 0.70 | 0.91   | 23.07  | 1.30      |
| FV9  | 38       | 0.72 | 0.92   | 21.97  | 1.27      |
| FV10 | 27       | 0.65 | 0.75   | 22.47  | 1.15      |
| FV11 | 28       | 0.69 | 0.79   | 10.12  | 1.14      |
| FV12 | 32       | 0.69 | 0.85   | 13.50  | 1.23      |
| FV13 | 34       | 0.71 | 0.90   | 21.34  | 1.26      |
| FV14 | 33       | 0.70 | 0.91   | 22.47  | 1.30      |
| FV15 | 31       | 0.69 | 0.90   | 20.22  | 1.30      |
| FV16 | 30       | 0.71 | 0.89   | 22.22  | 1.25      |

Table 3: Post compression parameter of liquisolid compacts

| Formulation Code | Hardness (kg/cm <sup>2</sup> ) | Weight Variation | % Friability | Thickness |
|------------------|--------------------------------|------------------|--------------|-----------|
| FV1              | 4.5                            | 575±3%           | 0.30         | 4.55±0.2  |
| FV2              | 4.5                            | 650±2.5%         | 0.30         | 4.93±0.1  |
| FV3              | 4.0                            | 750±1.5%         | 0.45         | 5.14±0.2  |
| FV4              | 4.5                            | 850±1%           | 0.35         | 5.85±0.6  |
| FV5              | 4.0                            | 440±2%           | 0.45         | 4.15±1.5  |
| FV6              | 4.0                            | 530±1.5%         | 0.80         | 4.25±0.6  |
| FV7              | 4.0                            | 630±2%           | 0.60         | 4.89±0.5  |
| FV8              | 3.5                            | 740±2.5%         | 0.50         | 5.15±0.25 |
| FV9              | 4.0                            | 245±4%           | 0.40         | 3.5±0.12  |
| FV10             | 4.5                            | 345±2.5%         | 0.45         | 3.75±0.15 |
| FV11             | 4.5                            | 455±2%           | 0.45         | 4.10±0.25 |
| FV12             | 4.0                            | 565±2%           | 0.40         | 4.45±0.35 |
| FV13             | 3.5                            | 175±4.5%         | 0.50         | 3.25±0.15 |
| FV14             | 3.0                            | 285±3%           | 0.55         | 3.65±0.14 |
| FV15             | 3.5                            | 400±2%           | 0.55         | 4.00±0.15 |
| FV16             | 3.5                            | 505±3%           | 0.70         | 4.2±0.22  |

Table 4: Disintegration and drug content of liquisolid compacts

| Formulation Code | Disintegration time (sec) | Drug Content Uniformity (%) |
|------------------|---------------------------|-----------------------------|
| FV1              | 325                       | 95.6±0.25                   |
| FV 2             | 328                       | 96.7±0.85                   |
| FV 3             | 330                       | 98.4±0.66                   |
| FV 4             | 300                       | 97.3±0.56                   |
| FV 5             | 355                       | 99.5±0.50                   |
| FV 6             | 345                       | 97.70±0.55                  |
| FV 7             | 350                       | 95.0±0.45                   |
| FV 8             | 320                       | 98.9±0.75                   |
| FV9              | 280                       | 99.1±0.85                   |
| FV10             | 115                       | 96.5±0.80                   |
| FV11             | 125                       | 97.0±0.90                   |
| FV12             | 285                       | 98.2±0.25                   |
| FV13             | 310                       | 99.0±0.10                   |
| FV14             | 325                       | 98.5±0.25                   |
| FV15             | 336                       | 98.3±0.50                   |
| FV16             | 340                       | 99.0±0.76                   |




Figure 1: in vitro dissolution of formulation fv10, marketed tablet and pure drug




Figure 2: FTIR of voriconazole drug




Figure 3: FTIR of voriconazole formulation




Figure 4: DSC of voriconazole drug




Figure 5: DSC of voriconazole lsc formulation




Figure 6: x-ray diffraction pattern of ezetimibe




Figure 7: X ray diffraction of Voriconazole drug




Figure 8: X-Ray Diffraction pattern of VoriconazoleLSC formulation without drug

Table 5: Stability study of optimized formulation FV10 at 40 °C/75% RH

| F. Code | After time (in days) | Hardness (kg/cm <sup>2</sup> ) | DT time (sec) | Thickness | Drug content | Friability % |
|---------|----------------------|--------------------------------|---------------|-----------|--------------|--------------|
| FV10    | 10                   | 4.5                            | 290           | 4.10±0.25 | 99.5±0.80    | 0.45         |
|         | 20                   | 4.5                            | 295           | 4.10±0.25 | 99.5±0.00    | 0.40         |
|         | 30                   | 4.5                            | 280           | 4.10±0.25 | 99.5±0.00    | 0.40         |

## REFERENCES

- Gangode BD, Ahirrao S, Chavan D, Jadhav A, Kshirsagar S, Liquisolid technique: an approach for enhancement of solubility. Indian Journal of Drugs; 2016; 4(4):149-167.
- Chella Naveen., Nalini Shastri., Rama Rao Tadikonda., Use of the liquisolid compact technique for improvement of the dissolution rate of valsartan. Acta Pharmaceutica Sinica B; 2012; 2(5):502-508.
- Fahmy RH., Kassem MA., Enhancement of famotidine dissolution rate through liquisolid tablets formulation: in-vitro and in-vivo evaluation. Eur J Pharm Biopharm.; 2008; 69(3):993-1003.
- Ramesh J., Vijaya kumar B, Narasimha Reddy Y, Formulation and evaluation of olanzapine liquisolid compact tablets, IJPT; 2016; 8(2):11780-11789.
- Arulkumaran J., Padmapreetha., Enhancement of solubility of Voriconazole by liquisolid technique. International Journal of Pharmaceutical Chemistry and Analysis; 2014; 1(1):14-38.
- Kaur M, Bala R, Arora S, Formulation and evaluation of liquisolid compacts of amlodipine besylate. IRJP; 2013; 4(1).
- Sandhya P., Shadab Khanam., Bhatnagar D, Rao Patnaik KSK, Subrahmanyam CVS, Formulation and Evaluation of Liquisolid Compacts of Carvedilol. IOSR Journal of Pharmacy and Biological Sciences; 2013; 6(5):26-36.
- Jamakandi VG, Kerur SS, Patil US, Formulation and Evaluation of Immediate Release Tablet of Carvedilol using Liquisolid Compacts Technique for Solubility Enhancement. Asian journal of Pharmaceutics. 2016; 10(3).
- Javadzadeh Y, SiahiShadbad MR, BarzegarJalali M, Nokhodchi A., Enhancement of dissolution rate of piroxicam using liquisolid compacts. Farmaco; 2005; 60(4):361-5
- Yousef javadzadeh., Mohammad reza siahi., Solmaz asnaashari., Ali nokhodchi. Liquisolid technique as a tool for enhancement of poorly water-soluble drugs and evaluation of their physicochemical properties. Acta Pharm.; 2007; 57:99-109.